COVID-19 versus seasonal influenza 2019–2020: USA

Gary P. Wormser

Summary Severe mitigation efforts in the USA to reduce the incidence of COVID-19 infections have led to a massive rise in unemployment, social disruption, and appear to be leading to a severe economic depression. In contrast, no such interventions were regarded as necessary to manage seasonal influenza in 2019–2020. Another mitigation approach is proposed for COVID-19 that would allow society to function and yet should still be effective.

Keywords Respiratory Virus · Coronavirus · SARS-CoV-2 · Pandemic · Mitigation

The pandemic of COVID-19 infections has caused numerous illnesses worldwide and attempts to mitigate the pandemic have severely disrupted many aspects of how society in the USA has functioned. The first case in the USA was diagnosed in January 2020 [1]. Mitigation efforts in the USA have focused on extreme measures for social distancing resulting in a large proportion of the healthy population asked or forced to remain at home. These measures have led to a massive rise in unemployment in the USA, caused tremendous social disruption, and appear to be leading to a severe economic depression. In addition, no clear end point or criteria for discontinuing these measures has been explicitly defined.

The current case load has demonstrated that many hospitals and medical centers in geographic areas in the USA with the most cases are not properly equipped to deal with the rapid emergence of a respiratory virus pandemic, which would appear to be a powerful impetus to reduce the new case load regardless of the impact of the interventions on the rest of society.

The USA has had to deal with respiratory virus pandemics before, with the worst one being the 1918–1919 influenza pandemic [2]; however, seasonal influenza in the USA in the time period from October 2019 until the present has not attracted very much media interest and with few to no interventions from the federal or local government in terms of shutting down the functionality of society. Some might be surprised to learn that the US Centers for Disease Control and Prevention estimated that from 1 October 2019 to 4 April 2020 up to 56 million cases of influenza have already occurred in the USA with up to 62,000 deaths (Table 1; [3–7]).

Strong mitigation efforts in certain cities in the USA reduced the number of cases of influenza in the 1918–1919 pandemic, but often cases recurred when the mitigation efforts were suspended or reduced [2]. An important consideration in terms of controlling respiratory virus outbreaks is the risk for development of a second wave of cases if insufficient herd immunity in the at-risk population has developed and if no vaccine has been developed.

Would an alternative mitigation effort in the USA for the COVID-19 pandemic of just quarantining cases and case contacts (with investigations of identified cases being done routinely and expeditiously to identify contacts), along with widespread adoption of hand hygiene and, perhaps, for a limited time period, with wearing a mask when outside of the home, be just as effective as the much more severe and disruptive restrictions currently being imposed [8, 9]? With this modified approach, no businesses would need to be closed, sporting events would continue, laboratories at universities and medical schools could...
Table 1  Comparison of seasonal influenza and COVID-19, USA, 2019–2020

| Variable                        | Influenza                                      | COVID-19                                      |
|---------------------------------|------------------------------------------------|------------------------------------------------|
| Virus type                      | Enveloped single-stranded RNA virus (negative sense) | Enveloped single-stranded RNA virus (positive sense) |
| Cell receptor                   | N-acetyl neuraminic acid                        | Angiotensin-converting enzyme 2; possibly also host cellular serine protease |
| Seasonal                        | Yes                                            | Unknown                                       |
| Precautions                     | Droplet a                                      | Airborne plus gowns, gloves, and eye protection |
| Duration of infectiousness      | From 1 day before illness to as long as severe symptoms persist; virus has been detected up to 21 days after onset of illness | Possibly from 3 days before onset of symptoms in some cases until clearance of the virus |
| Treatment options               | Yes (multiple FDA-approved drugs)               | No established therapies                      |
| Vaccine                         | Yes                                            | No                                            |
| Incubation time: Exposure to onset of symptoms | 1–4 days, median 2 days                         | 2–14 days                                     |
| Pregnant patients at high risk for severe illness | Yes                                            | ?No                                           |
| Children at risk for severe illness | Yes                                            | ?No                                           |
| Number of cases USA             | 39–56 million cases (10/1/19–4/4/20)           | 740,557 (4/19/20) b                           |
| Number of deaths USA            | 24,000–62,000 (10/1/19–4/4/20) (up to 0.16% of cases) | 38,979 (4/19/20) (5.3% of cases) b            |

a Aerosol transmission may be possible but is controversial and may be dependent on the strain of influenza virus [5, 7]

b The number of cases listed is likely to be a serious underestimate of the total number of infections given the infrequency of testing persons not admitted to a hospital in the USA. Therefore, the percentage of deaths listed is likely to greatly overestimate the actual percentage

continue to do their important research studies, and group gatherings would be allowed. With this alternative, and far less disruptive, approach all persons with fever and/or cough and/or shortness of breath, as well as those with any other unexplained symptom (e.g., fatigue or malaise or gastrointestinal symptoms), would be asked to stay at home for a defined period of time (typically ≤14 days but duration would depend on the specific circumstances) and contact their healthcare provider. These measures, while somewhat burdensome, are much less so than the ones currently in place.

Although it could be argued that self-quarantining only those persons with symptoms, or who have had contact with a possible COVID-19 case, including even those whose only contact occurred during the 72-h period before the onset of symptoms in the person with possible COVID-19 infection, might not completely eliminate the spread of the virus, it is certainly likely to reduce substantially the spread of the infection to others [4, 5, 8–14]. Self-quarantining is suggested of persons exposed to a patient with COVID-19 infection even if exposure only occurred during the 72-h period before illness began, because certain evidence exists that infected, but asymptomatic, persons can potentially spread the virus [4, 13, 14]. Unresolved questions in respect to this issue are how often transmission occurs from asymptomatic patients prior to this 72-h time period and how often and for how long asymptomatic patients might continue to spread the virus without ever becoming symptomatic. In general, however, the available data with respect to transmission of COVID-19 by asymptomatic but infected persons indicate that the frequency of this event and the number of resulting secondary cases would be too low to substantively negatively impact mitigation of the pandemic by the more limited control measures proposed above [8, 13, 14].

Acknowledgements The author thanks Julia Singer, Lisa Giarratano, Dr. Doris Bucher, and Stanley H. Weiss, M.D. for their assistance.

Conflict of interest G.P. Wormser reports receiving research grants from Immunetics, Inc., Institute for Systems Biology, Rarecyte, Inc., and Quidel Corporation. He owns equity in Abbott/AbbVie; has been an expert witness in malpractice cases involving Lyme disease; and is an unpaid board member of the American Lyme Disease Foundation.

References

1. Holshue ML, DeBolt C, Lindquist S, et al. First case of 2019 novel coronavirus in the United States. N Engl J Med. 2020;382:929–36.
2. Bootsma MCJ, Ferguson NM. The effect of public health measures in the 1918 influenza pandemic in US cities. Proc Natl Acad Sci USA. 2007;104:7588–93.
3. Li H, Zhou Y, Zhang M, Wang H, Zhao O, Liu J. Updated approaches against SARS-CoV-2. Antimicrob Agents Chemother. 2020; https://doi.org/10.1128/AAC.00483-20.
4. Kimball A, Hatfield KM, Arons M, et al. Asymptomatic and presymptomatic SARS-CoV-2 infections in residents of a long-term care skilled nursing facility—King County, Washington, March 2020. MMWR Morb Mortal Wkly Rep. 2020;69:377–81.
5. Tellier R, Li Y, Cowling BJ, Tang JW. Recognition of aerosol transmission of infectious agents: a commentary. BMC Infect Dis. 2019;19:101. https://doi.org/10.1186/s12879-019-3707-y.
6. Czumbel I, Quinten C, Lopalco P, Semenza JC, ECDC-expert panel working group. Management and control of communicable diseases in schools and other child care settings: systematic review on the incubation period and period of infectiousness. BMC Infect Dis. 2018;18:199. https://doi.org/10.1186/s12879-018-3095-8.

7. Kutter JS, Spronken MI, Fraaij PL, Fouchier RAM, Herfst S. Transmission routes of respiratory viruses among humans. Curr Opin Virol. 2018;28:142–51.

8. Hellewell J, Abbott S, Gimma A, et al. Feasibility of controlling COVID-19 outbreaks by isolation of cases and contacts. Lancet. 2020;8:e488–e96.

9. Jefferson T, Del Mar CT, Dooley L, etaI. Physical interventions to interrupt or reduce the spread of respiratory viruses (review). Cochrane Database Syst Rev. 2011;7:CD6207. https://doi.org/10.1002/14651858.CD006207.

10. Moura da Silva AA. On the possibility of interrupting the coronavirus (COVID-19) epidemic based on the best available evidence. Rev bras epidemiol. 2020;23:E200021. https://doi.org/10.1590/1980-549720200021.

11. Cowling BJ, Fang VJ, Riley S, Malik Peiris JS, Leung GM. Estimation of the serial interval of influenza. Epidemiology. 2009;20:344–7.

12. Zou L, Ruan F, Huang M, et al. SARS-CoV-2 viral load in upper respiratory specimens of infected patients. N Engl J Med. 2020;382:1177–9.

13. Wei WE, Li Z, Chiew CJ, Yong SE, Toh MP, Lee VL. Presymptomatic transmission of SARS-CoV-2—Singapore January 23—March 16, 2020. Mmwr Morb Mortal Wkly Rep. 2020;69:411–5.

14. Thompson R. Pandemic potential of 2019-nCOV. Lancet Infect Dis. 2020;20:280.

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.